AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (original) A tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative having the general Formula I



Formula I

Wherein

X is CH_2, O or S;

R represents 1-3 substituents independently selected from H, (C_{1-4})alkyl, (C_{1-4})alkyloxy and halogen;

R_1 is (C_{5-8})cycloalkyl;

R_2 is H or (C_{1-4})alkyl;

R_3, R_3', R_4, R_4', R_5, R_5' and R_6' are independently hydrogen or (C_{1-4})alkyl, optionally substituted with (C_{1-4})alkyloxy, OH or halogen;

R_6 is hydrogen or (C_{1-4})alkyl, optionally substituted with (C_{1-4})alkyloxy, OH or halogen; or

R_6 forms together with R_7 a 4-7 membered saturated heterocyclic ring, optionally containing a further heteroatom selected from O and S;

R_7 forms together with R_6 a 4-7 membered saturated heterocyclic ring, optionally containing a further heteroatom selected from O and S; or

R_7 is H, (C_{1-4})alkyl or (C_{3-5})cycloalkyl, the alkyl groups being optionally substituted with OH, halogen or (C_{1-4})alkyloxy; or a pharmaceutically acceptable salt thereof.

2. (original) The tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 1, wherein R is H and R_1 is cyclopentyl or cyclohexyl.

3. (currently amended) The tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 1 [or 2], wherein X is CH_2 or O.

4. (currently amended) The tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of [any one of claims 1-3] claim 1, wherein R, R_2, R_3, R_3', R_4', R_5, R_5' and R_6' are H; R_4, R_6 and R_7 are independently H or (C_{1-4})alkyl; or R_6 forms together with R_7 a 5- or 6-membered saturated heterocyclic ring and R_4 is H or (C_{1-4})alkyl.

5. (cancelled)

6. (currently amended) A pharmaceutical composition comprising a tricyclic 1-[(indol-3-yl)-carbonyl]piperazine derivative of [any one of claims 1-4] claim 1 together with a pharmaceutically acceptable carrier therefor.

7. (cancelled)

8. (new) The tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 2, wherein X is CH_2 or O.

9. (new) The tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 2, wherein R, R_2, R_3, R_3', R_4', R_5, R_5' and R_6' are H; R_4, R_6 and R_7 are independently H or (C_{1-4})alkyl; or R_6 forms together with R_7 a 5- or 6-membered saturated heterocyclic ring and R_4 is H or (C_{1-4})alkyl.

10. (new) The tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 3, wherein R, R_2, R_3, R_3', R_4', R_5, R_5' and R_6' are H; R_4, R_6 and R_7 are independently H or (C_{1-4})alkyl; or R_6 forms together with R_7 a 5- or 6-membered saturated heterocyclic ring and R_4 is H or (C_{1-4})alkyl.

11. (new) A method of treating pain in a patient in need of such treatment, comprising:
administering an effective amount of the compound according to claim 1.

12. (new) A method of activating a cannibinoid CB1 receptor in a patient in need thereof, comprising:
administering an effective amount of the compound according to claim 1.